Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» ReViral Completes $55 Million Series B Round to Advance RSV Treatment
ReViral Completes $55 Million Series B Round to Advance RSV Treatment
ReViral Completes $55 Million Series B Round to Advance RSV Treatment
Submitted by
admin
on August 1, 2018 - 10:45am
Source:
CP Wire
News Tags:
ReViral
RSV
RV521
Headline:
ReViral Completes $55 Million Series B Round to Advance RSV Treatment
snippet:
RSV causes 30 million infections and 200,000 deaths worldwide in children under 5 alone
The company's lead candidate, RV521, is currently in Ph II trials
Do Not Allow Advertisers to Use My Personal information
